Hoạt động kháng khuẩn và độc tính thận của hai dẫn xuất 2″-amino mới của arbekacin

Kondo S, Iinuma K, Yamamoto H, Maeda K, Umezawa H. Syntheses of 1-N-{(S)-4-amino-2-hydroxybutyryl}-kanamycin B and-3',4'-dideoxykanamycin B active against kanamycin-resistant bacteria. J Antibiot 1973;26:412–415. Umezawa H, Kondo S. Mechanisms of resistance to aminoglycoside antibiotics. In: Umezawa H, Hooper IR (eds) Handbook of experimental pharmacology. Vol 62. Aminoglycoside antibiotics. New York:Springer-Verlag, 1982;267–292. Umezawa H, Kondo S. Aminoglycosides. In: Kuemmerle (ed) Clinical chemotherapy. II. New York:Thien-Stratton, 1984;120–146. Ubukata K, Yamashita N, Gotoh A, Konno M. Purification and characterization of aminoglycoside-modifying enzymes fromStaphylococcus aureus andStaphylococcus epidermidis. Antimicrob Agents Chemother 1984;25:754–759. Kobayashi Y, Uchida H, Kawakami Y. Arbekacin. Int J Antimicrob Agents 1995;5:227–230. Kondo S, Tamura A, Gomi S, Ikeda Y, Takeuchi T, Mitsuhashi S. Structures of enzymatically modified products of arbekacin by methicillin-resistantStaphylococcus aureus. J Antibiot 1993;46:310–315. Kondo S, Shibahara S, Usui T, Kudo T, Tamura A, Gomi S, et al. New 2″-amino derivatives of arbekacin, potent aminoglycoside antibiotics against methicillin-resistantStaphylococcus aureus. J Antibiot 1993;46:531–534. Kondo S, Ikeda Y, Ikeda D, Takeuchi T, Usui T, Ishii M, et al. Synthesis of 2″-amino-2″-deoxyarbekacin and its analogs having potent activity against methicillin-resistantStaphylococcus aureus. J Antibiot 1994;47:821–832. Kondo S, Ikeda Y, Hattori S, Hamada M, Takeuchi T. Susceptibility of methicillin-resistantStaphylococcus aureus to various antibiotics: classification by aminoglycosidemodifying enzymes and antibiotics active against MRSA. Jpn J Antibiot 1991;44:1211–1215 (in Japanese). Karber G. Betrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Pathol Pharmacol 1931;162:480. Umezawa H, Iwasawa H, Ikeda D, Kondo S. A predominant role of amino groups in the antibacterial action of aminoglycosides: synthesis of hexa-and heptadeoxykanamycin derivatives. J Antibiot 1983;36:1087–1091. Price KE. Aminoglycoside research 1975–1978: prospects for development of improved agents. Antimicrob Agents Chemother 1986;29:543–548. Tulkens PM. Nephrotoxicity of aminoglycoside antibiotics. Toxicol Lett 1989;46:107–123. Kaloyanides GJ. Metabolic interactions between drugs and renal tubuklointerstitial cells: role in nephrotoxicity. Kidney Int 1991;39:531–540. Kitasato I, Niizato T, Inouye S. Effect of glucarolactam on low-dose nephrotoxicities of dibekacin and gentamicin in Fischer rats. Drugs Exp Clin Res 1989;15:249–259. Kitasato I, Niizato T, Watanabe T, Inouye S. Reduction of dibekacin-induced nephrotoxicity in the rats by the formation of N-alkylsulfonate derivatives. Drugs Exp Clin Res 1989;15:239–247. Powell SH, Thompson WL, Luthe MA, Stern RC, Grossniklaus DA, Bloxham DD, et al. Once-daily vs. continuous aminoglycoside dosing: efficacy and toxicity in animal and clinical studies of gentamicin, netilmicin, and tobramycin. J Infect Dis 1983;147:918–932. Verpooten GA, Giuliano RA, Verbist L, Eestermans G, DeBroe ME. Once-daily dosing decreases renal accumulation of gentamicin and netilmicin. Clin Pharmacol Ther 1989;45:22–27. Mitomi N, Komiya I, Okamoto J. Pharmacokinetic study on the distribution of arbekacin into the rat kidneys. Sci Rep Meiji Seika Kaisha 1991;30:14–19 (in Japanese). Carlier MB, Laurent G, Claes PJ, Vanderhaeghe HJ, tulkens PM. Inhibition of lysosomal phospholipases by aminoglycoside antibiotics: in vitro comparative studies. Antimicrob Agents Chemother 1983;23:440–449. Williams PD, Bennett DB, Gleason CR, Hottendorf GH. Correlation between renal membrane binding and nephrotoxicity of aminoglycosides. Antimicrob Agents Chemother 1987;31:570–574.